TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03062423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofodelevier
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (fist dose)
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi (second dose)
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT01069276

Intervention type: OTHER
Intervention: No intervention in this study
Description: No intervention in this study
Study: NCT00554606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab
Study: NCT02988128

Intervention type: DEVICE
Intervention: Treatment for intracranial aneurysms
Description: Embolization of aneurysms

Intervention type: DEVICE
Intervention: Treatment for Acute Ischemic Stroke
Description: Revascularization of an intracranial blood vessel
Study: NCT03903809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegol-Sihematide
Description: Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPO
Description: Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
Study: NCT04961463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Study: NCT02240030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 High Dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02535871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121 Lotion
Description: Investigational Product: IDP-121 Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: Comparator Product: IDP-121 Vehicle Lotion
Study: NCT02188173

Intervention type: DRUG
Intervention: dexamethasone 700 ㎍ intravitreal implant
Description: Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
Study: NCT02376543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 Gauge EUS FNA BNX
Description: There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 Gauge EUS FNA BNX
Description: There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
Study: NCT03771248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peek telescopic partial denture
Description: removable partial denture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peek telescopic partial denture
Description: removable partial denture
Study: NCT04759053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB
Description: Fine needle aspiration from the nodules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB
Description: Fine needle aspiration from the nodules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core biopsy
Description: Core biopsy from thyroid nodules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core biopsy
Description: Core biopsy from thyroid nodules
Study: NCT00416650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: All patients will receive 150 mg orally daily
Study: NCT04851938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation device
Description: The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation device
Description: The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation device
Description: The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation device
Description: The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
Study: NCT01906450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus Azithromycin
Description: Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing plus placebo
Description: Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
Study: NCT00906386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: oral, 1 mg twice daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 1 mg twice daily, 12 weeks
Study: NCT02087189

Intervention type: DEVICE
Intervention: First ICD/CRT-D implantation or upgrade from pacemaker
Study: NCT01140503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 20mg PO BID
Study: NCT00811356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK932121; Rosiglitazone; Rosuvastatin
Description: GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
Study: NCT03981419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRF6021
Description: for IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for IV infusion
Study: NCT01110135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT03283462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure
Description: Mitopure (Urolithin A) containing softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing softgels
Study: NCT00883909

Intervention type: DRUG
Intervention: dutasteride
Description: A follow-up study in adult male subjects who have received investigational product
Study: NCT04312386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMAT
Description: Baseline menue, not optimized
Study: NCT04471025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG guided infraclavicular block
Description: USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG guided infraclavicular block
Description: USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
Study: NCT02346591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jauntly
Description: Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online stress management information
Description: Online educational information about stress management
Study: NCT01242995

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope
Description: Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
Study: NCT03487952

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
Study: NCT03659292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GEA
Description: Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCEA
Description: Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: GA
Description: General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: PCIA
Description: Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
Study: NCT05256524

Intervention type: DRUG
Intervention: The effect of LMWH
Description: Quantified by aFXa-levels

Intervention type: DRUG
Intervention: The effect of LMWH
Description: Quantified by aFXa-levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring frequency of aFXa-levels
Description: The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring frequency of aFXa-levels
Description: The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
Study: NCT01930565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFCO application
Description: Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TTO application
Description: Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
Study: NCT01246063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03457935

Intervention type: OTHER
Intervention: blood samples
Description: Blood samples

Intervention type: OTHER
Intervention: blood samples
Description: Blood samples

Intervention type: OTHER
Intervention: blood samples
Description: Blood samples
Study: NCT03715361

Intervention type: DIAGNOSTIC_TEST
Intervention: SL-ECG
Description: additional SL-ECG measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: SL-ECG
Description: additional SL-ECG measurement
Study: NCT02080013

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: radiofrequency
Description: ClosureFAST

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: radiofrequency
Description: ClosureFAST
Study: NCT03156335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
Study: NCT01200992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3348
Description: Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
Study: NCT03031886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low glycaemic index intervention
Description: Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high glycaemic index intervention
Description: High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
Study: NCT02212379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and etravirine
Description: Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal.
Study: NCT00839254

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine Synflorix (GSK1024850A)
Description: 2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine Synflorix (GSK1024850A)
Description: 2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine Synflorix (GSK1024850A)
Description: 2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine Synflorix (GSK1024850A)
Description: 2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
Description: 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
Description: 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
Description: 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
Description: 2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
Study: NCT02926482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescriber Recruitment Bundle (PRB)
Description: The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
Study: NCT02419144

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AMI and campaigns
Description: The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AMI and campaigns
Description: The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
Study: NCT01782300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV003 Vaccine
Description: TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
Study: NCT03194841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart failure application
Description: A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
Study: NCT01129843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Directly observed home based daily iron therapy
Description: Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Directly observed home based daily iron therapy
Description: Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
Study: NCT01156142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxepin hydrochloride
Description: Oral rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral rinse
Study: NCT03590912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 50 Mcg/Inh Nasal Spray
Description: One spray in each nostril once daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)
Description: Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug (prednisolone)
Description: This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.